Study S001127

Effects of Degludec/Liraglutide on Time in Range, Markers of Inflammation and Endothelial Dysfunction Compared to Scheme Insulin Basal Bolus, in a Population of Diabetic Inpatients and Possible Correlation With Intra-hospital Mortality Rates

ClinicalTrials.gov record

Registration

Registration: NCT05360537
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: DOUBLE
Status: COMPLETED
Enrollment: 100
Start: 2021-04-01
Primary completion: 2021-12-01
Lead sponsor: University of Palermo
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Insulin Degludec / Liraglutide Injectable Product; DRUG:Insulin Glargine
Results posted: FALSE

Registered primary outcomes

Change of Time in Range % at 7 days, at 1 and 6 months [7 days, 1 months and 6 months]
Change of hypoglycemic events [7 days, 1 months and 6 months]
Change from Baseline Reactive Hyperemia Index at 3 and 9 months [7 days, 1 months and 6 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.